Document Detail


Sensor-Augmented Pump Therapy at 36 Months.
MedLine Citation:
PMID:  23016516     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Abstract Background: This follow-up study investigates the metabolic and psychosocial effects of sensor-augmented pump (SAP) therapy in adults with type 1 diabetes 36 months after therapy start. Subjects and Methods: We invited all 24 Danish adults with type 1 diabetes who had previously participated in the European multicenter randomized controlled Eurythmics Trial. Thirteen of the 24 patients started SAP therapy during the Eurythmics Trial; 11 patients were controls but started using SAP immediately after completion of the trial. In the current study, we estimated the effects of SAP 36 months after therapy start by change in glycated hemoglobin (HbA1c) and diabetes questionnaire scores (Diabetes Treatment Satisfactions Questionnaire [DTSQs], Problem Areas in Diabetes [PAID] questionnaire, and Hypoglycemia Fear Survey [HFS]). Results: At 36 months, 16 of the 24 patients were still using SAP, 14 of them >70% of time. The HbA1c level decreased from 8.7% at therapy start to 7.3% at 36 months (P<0.0001). Similar reductions in HbA1c were obtained regardless of whether SAP therapy was initiated during or after the Eurythmics Trial. DTSQs, PAID questionnaire, and HFS scores improved by 9.0 (P<0.0001), -10.8 (P=0.013), and -5.5 (P=0.152), respectively, in the 16 SAP users. Conclusions: This study documents persisting beneficial effects of SAP on HbA1c, treatment satisfaction, magnitude of diabetes-related problems, and fear of hypoglycemia 36 months after therapy start. The follow-up is considerably longer than in other published studies; still, the results are in line with the positive short-term outcomes of larger studies of SAP use.
Authors:
Signe Schmidt; Kirsten Nørgaard
Related Documents :
23468086 - Economic costs of diabetes in the u.s. in 2012.
23074416 - Continuous glucose monitoring for patients with diabetes: an evidence-based analysis.
1961646 - Detecting and treating retinopathy in patients with type i diabetes mellitus. savings a...
24731666 - Combating the dual burden: therapeutic targeting of common pathways in obesity and type...
10865836 - Roles of the age-rage system in vascular injury in diabetes.
2531916 - On the pathogenesis of arterial blood pressure elevation early in the course of diabeti...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-9-27
Journal Detail:
Title:  Diabetes technology & therapeutics     Volume:  -     ISSN:  1557-8593     ISO Abbreviation:  Diabetes Technol. Ther.     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-9-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100889084     Medline TA:  Diabetes Technol Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Endocrinology, Copenhagen University Hospital , Hvidovre, Hvidovre, Denmark .
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Test-Retest, Responsiveness, and Minimal Important Change of the Ability to Perform Physical Activit...
Next Document:  Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT)...